Benzo's Increase Hip Fracture Rates in the Elderly
Credit: Cardiff univeristy
Older people newly prescribed sleeping pills like benzodiazepines and ‘Z-drugs’ have over double the odds of a hip fracture in the first two weeks compared with non-users, according to a new study by researchers at Cardiff University and King’s College London.
Dr Ben Carter, Cardiff University’s School of Medicine and the Institute of Psychiatry, Psychology and Neuroscience, King’s College London, explains: “While ‘Z-drugs are fast becoming the doctor’s hypnotic prescription of choice, there is no evidence that they are a safer alternative to benzodiazepines in relation to hip fracture risk.”
“Our study shows that both appear to significantly increase the risk of hip fracture when newly prescribed by doctors.”
The study of people aged over 65 found that new users of these hypnotic medicines experienced nearly two and a half times the fracture rate, when compared with older people not taking hypnotics. An estimated 53% increase in fracture risk was identified in medium-term users (15 to 30 days), as well as a 20% increased risk of hip fracture in long-term users (greater than 30 days).
Dr Carter added: “Careful consideration of the immediate increased risk of hip fracture should inform the clinical decision-making process...”
“Clinically effective measures like strength training to improve frailty, removal of hazards at home, visual correction and a medication review are also needed to mitigate the risk of hip fractures, particularly in the first few days of use.”
The research supports previous studies linking use of hypnotics by older people with an increased risk of accidents, dependence, cognitive decline and hip fracture. The drugs are also thought to cause drowsiness, delayed reaction times and impaired balance.
Donnelly, K., Bracchi, R., Hewitt, J., Routledge, P. and Carter, B. (2017). Benzodiazepines, Z-drugs and the risk of hip fracture: A systematic review and meta-analysis. PLOS ONE, 12(4), p.e0174730.
This article has been republished from materials provided by Cardiff University. Note: material may have been edited for length and content. For further information, please contact the cited source.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
BioAscent Announces New CEO and Plans to Expand Discovery Services OfferingNews
BioAscent Discovery Limited appoints new CEO, Paul Smith in preparation for the expansion of companies discovery services.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018